Biomarker research collaboration

May 5, 2010

Thermo Fisher Scientific and Professor Bruno Domon, director of the new Luxembourg Clinical Proteomics unit (LCP), have announced a collaboration to develop workflows to overcome current bottlenecks in biomarker discovery and assay development for clinical proteomics research.

Thermo Fisher Scientific and Professor Bruno Domon, director of the new Luxembourg Clinical Proteomics unit (LCP), have announced a collaboration to develop workflows to overcome current bottlenecks in biomarker discovery and assay development for clinical proteomics research.

“This collaboration provides a unique opportunity for the company to expand its role in the development of cutting-edge biomarker research tools and consolidate its presence within the EU,” said Ian Jardine, the company’s vice president of global R&D.

Located at the Public Research Centre for Health (CRP-Santé), the research group will employ a recently introduced hybrid mass spectrometer equipped with electron transfer dissociation for biomarker discovery. According to the company the instrument enables the massive, rapid and accurate identification of proteins in complex mixtures and the characterization of post-translational modifications. These capabilities are central to the creation of a second-generation biomarker discovery and validation workflow.

In addition, the group will use a triple stage quadrupole mass spectrometer for fast, sensitive, accurate and reliable targeted protein quantification, a benchtop LC–MS for biomarker profiling analyses.

“By joining forces, I hope to build on our results to further develop workflows that will enable researchers to overcome challenges in biomarker discovery and verification,” said Professor Domon.

For more information on the company visit: www.thermo.com

Related Content:

News